Molecular analysis of the human thrombin-activatable fibrinolysis inhibitor gene promoter

被引:12
|
作者
Garand, Mathieu
Bastajian, Nazareth
Nesheim, Michael E.
Boffa, Michael B.
Koschinsky, Marlys L.
机构
[1] Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada
[2] Queens Univ, Dept Med, Kingston, ON K7L 3N6, Canada
关键词
thrombin-activatable fibrinolysis inhibitor; fibrinolysis; transcription; liver; gene regulation;
D O I
10.1111/j.1365-2141.2007.06640.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Thrombin-activatable fibrinolysis inhibitor (TAFI) is a carboxypeptidase B-like pro-enzyme that, once activated, attenuates fibrinolysis. Little is presently known of the factors that regulate expression of CPB2, the gene encoding TAFI. This study identified 10 potential transcription factor binding sites (denoted A -J) within the proximal promoter region of CPB2, spanning nucleotides -425 to + 21; two of these represent previously-described binding sites for CCAAT/enhancer binding protein and glucocorticoid receptor. We identified additional transcription factors that bind within the proximal CPB2 promoter, namely, nuclear factor-Y (NF-Y) and hepatocyte nuclear factor-1 alpha (HNF-1 alpha). Binding of NF-Y to the region between nucleotides -76 to -59 (Site B) is important for basal CPB2 promoter activity; NF-Y may be a key factor for the recruitment of the transcriptional machinery to the TAFI gene promoter. HNF-1 alpha binds at the interface between Sites C and B. Transient transfections of CPB2 promoter-reporter constructs showed that HNF-1 alpha binding is essential for the activity of this promoter in HepG2 cells, indicating that HNF-1 alpha is involved in the liver-specific expression of CPB2.
引用
收藏
页码:231 / 244
页数:14
相关论文
共 50 条
  • [1] Thrombin-activatable fibrinolysis inhibitor
    Marx, PF
    CURRENT MEDICINAL CHEMISTRY, 2004, 11 (17) : 2335 - 2348
  • [2] Is there thrombin-activatable fibrinolysis inhibitor in saliva?
    Chopra, S.
    Friman, E.
    Krueger, C. W.
    Antovic, J. P.
    Naimi-Akbar, A.
    BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY, 2020, 58 (09): : E33 - E37
  • [3] Elucidation of the molecular mechanisms of two nanobodies that inhibit thrombin-activatable fibrinolysis inhibitor activation and activated thrombin-activatable fibrinolysis inhibitor activity
    Zhou, X.
    Weeks, S. D.
    Ameloot, P.
    Callewaert, N.
    Strelkov, S. V.
    Declerck, P. J.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2016, 14 (08) : 1629 - 1638
  • [4] Insights into the molecular inactivation mechanism of human activated thrombin-activatable fibrinolysis inhibitor
    Sanglas, L.
    Arolas, J. L.
    Valnickova, Z.
    Aviles, F. X.
    Enghild, J. J.
    Gomis-Ruth, F. X.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2010, 8 (05) : 1056 - 1065
  • [5] Regulation of the gene encoding human thrombin-activatable fibrinolysis inhibitor by estrogen and progesterone
    Garand, Mathieu
    Lin, Joellen H. H.
    Zagorac, Branislava
    Koschinsky, Marlys L.
    Boffa, Michael B.
    BLOOD COAGULATION & FIBRINOLYSIS, 2013, 24 (04) : 393 - 404
  • [6] The effects of hyperglycaemia on thrombin-activatable fibrinolysis inhibitor
    Verkleij, C. J. N.
    Nieuwdorp, M.
    Gerdes, V. E. A.
    Morgelin, M.
    Meijers, J. C. M.
    Marx, P. F.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 392 - 392
  • [7] Characterization of mouse thrombin-activatable fibrinolysis inhibitor
    Marx, PF
    Wagenaar, GTM
    Reijerkerk, A
    Tiekstra, MJ
    van Rossum, AGSH
    Gebbink, MFBG
    Meijers, JCM
    THROMBOSIS AND HAEMOSTASIS, 2000, 83 (02) : 297 - 303
  • [8] Thrombin-activatable fibrinolysis inhibitor in hypothyroidism and hyperthyroxinaemia
    Verkleij, Chantal J. N.
    Stuijver, Danka J. F.
    van Zaane, Bregje
    Squizzato, Alessandro
    Brandjes, Dees P. M.
    Buller, Harry R.
    Meijers, Joost C. M.
    Gerdes, Victor E. A.
    THROMBOSIS AND HAEMOSTASIS, 2013, 109 (02) : 214 - 220
  • [9] The effects of hyperglycaemia on thrombin-activatable fibrinolysis inhibitor
    Verkleij, Chantal J. N.
    Nieuwdorp, Max
    Gerdes, Victor E. A.
    Morgelin, Matthias
    Meijers, Joost C. M.
    Marx, Pauline F.
    THROMBOSIS AND HAEMOSTASIS, 2009, 102 (03) : 460 - 468
  • [10] Polymorphisms in the thrombin-activatable fibrinolysis inhibitor gene and risk of venous thromboembolism
    Hooper, W. C.
    Dowling, N.
    DeStaercke, C.
    Whitsett, C.
    Miller, C.
    Beckman, M.
    Austin, H.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 1042 - 1042